Medications for Ankylosing Spondylitis
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Ankylosing Spondylitis.
Found 24 Approved Drugs for Ankylosing Spondylitis
Infliximab
Brand Names
Zymfentra, Inflectra, Avsola, Remicade, Renflexis
Infliximab
Brand Names
Zymfentra, Inflectra, Avsola, Remicade, Renflexis
Form: Injection, Kit
Method of administration: Subcutaneous, Intravenous
FDA approval date: August 24, 1998
Classification: Tumor Necrosis Factor Blocker
ZYMFENTRA is a tumor necrosis factor (TNF) blocker indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. ( 1 ) moderately to severely active Crohn’s disease following treatment with an infliximab products administered intraneously. ( 1 ) ZYMFENTRA is indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. moderately to severely active Crohn's disease following treatment with an infliximab product administered intravetnously.
Adalimumab
Brand Names
Adalimumab-aacf, Humira
Adalimumab
Brand Names
Adalimumab-aacf, Humira
Form: Kit
Method of administration: Subcutaneous
FDA approval date: December 31, 2002
HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
Enbrel
Generic Name
Etanercept
Enbrel
Generic Name
Etanercept
Form: Solution
Method of administration: Subcutaneous
FDA approval date: June 07, 2019
Classification: Tumor Necrosis Factor Blocker
Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with: Rheumatoid Arthritis (RA).
Adalimumab-AATY
Brand Names
Yuflyma, Adalimumab
Adalimumab-AATY
Brand Names
Yuflyma, Adalimumab
Form: Kit
FDA approval date: May 23, 2023
Adalimumab-aaty is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid arthritis.
Adalimumab-ADAZ
Brand Names
Amjevita, Adalimumab-bwwd, Adalimumab, Yusimry, Hyrimoz, Hadlima
Adalimumab-ADAZ
Brand Names
Amjevita, Adalimumab-bwwd, Adalimumab, Yusimry, Hyrimoz, Hadlima
Form: Injection, Kit, Solution
Method of administration: Subcutaneous
FDA approval date: January 31, 2023
Classification: Tumor Necrosis Factor Blocker
YUSIMRY is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
Showing 1-5 of 24
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances